Evogene
Business Services · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Gad Feinstein St. Park 13 Rehovot, Rehov...Phone Number
+972 89311900Website
www.evogene.comRevenue
$8.5 MillionStock Symbol
EVGNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Evogene
Founded in 1999, based in Rehovot, Israel, Evogene is a computational biology company developing life-science based products using its proprietary AI-driven technological engines - MicroBoost AI, ChemPass AI, and GeneRator AI - to accelerate discovery in microbes, small molecules, and genetic elements. Through its subsidiaries and strategic partners, Evogene applies these platforms to human therapeutics, ag-chemicals, and industrial-scale agriculture.Explore more
Evogene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evogene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Evogene has new funding data
Click to see if Evogene had a recent Job posting/layoffs
Check out if Evogene is spiking on competitors!
Earning: See what the market has to say on Evogene recently announced quarterly report
Check if Evogene has recently received funding, and reach out quickly before it becomes old news!
Evogene, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Evogene launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Evogene
Recommended Actions
Find VP level buyers at Evogene
Find more new buyers
Company Profile Activity
Activity Insights
Evogene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Evogene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Evogene.
Evogene financials insights
Gather financial insights about Evogene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$5M
2020
Share Placement
$10M
Evogene Tech Stack
A closer look at the technologies used by Evogene
See more technologies
Most Recent Scoops
Partnership
Evogene has announced its second collaboration with Google Cloud, initiated in February 2026, to integrate advanced AI agents into ChemPass AI using Google Cloud Vertex AI. The collaboration aims to decrease manual errors and automate complex scientific workflows to improve novel small molecule candidate probability of development success.
Cloud, Machine Learning, Artificial Intelligence
Project
Evogene is advancing multiple partnered drug discovery programs with biotechnology companies and academic institutions in human health. ChemPass AI is driving discovery and optimization of candidates that are progressing into testing with partners, with four collaborations publicly disclosed to date.
Medical Research, Pharmaceuticals, Artificial Intelligence
Earnings
reported total operating expenses net of approximately $13.8 million for the year ended 2025, compared to approximately $22 million in 2024, reflecting a significant decrease due to organizational realignment and cost reduction initiatives.
Spending/Investment, Finance, Financial Operations
Partnership
Evogene has successfully completed its first collaboration with Google Cloud in mid-2025, delivering a first-in-class foundation model for the generation of novel molecular product candidates. By processing a database of 38 billion structures, the collaboration tripled benchmarks for accuracy, delivering 90% design precision.
Cloud, Partnership, Machine Learning, Pharmaceuticals, Artificial Intelligence
Divestiture
Divestitures, Finance, Financial Operations
Evogene News & Media
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small...Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q1 2026 Earnings Call May 20, 2026 9:00 AM EDTCompany ParticipantsOfer Haviv - CEO, President & DirectorGabi Tarcic - Chief...Evogene Reports First Quarter 2026 Financial Results
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and...Evogene to Present at the 24th Schrödinger European User Group Meeting
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evogene
Sign Up For FreeTo access detailed company insights
Founded in 1999, based in Rehovot, Israel, Evogene is a computational biology company developing life-science based products using its proprietary AI-driven technological engines - MicroBoost AI, ChemPass AI, and GeneRator AI - to accelerate discovery in microbes, small molecules, and genetic elements. Through its subsidiaries and strategic partner... Read More
